(Q56806516)

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

An Inventory for Measuring Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Credibility of analogue therapy rationales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Respiratory control as a treatment for panic attacks.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Reliability of DSM-III anxiety disorder categories using a new structured interview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Discontinuation of alprazolam treatment in panic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Relaxation-induced anxiety: Mechanisms and theoretical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Assessment of agoraphobia--II. Measurement of clinical change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

The hyperventilation syndrome. A pilot study on the effectiveness of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Agoraphobia, the panic attack and the hyperventilation syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Brief standard self-rating for phobic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Applied relaxation vs progressive relaxation in the treatment of panic disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

A case of panic disorder treated with breathing retraining.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Respiratory control in the treatment of panic attacks: replication and extension with concurrent measurement of behaviour and pCO2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Patterning of Cognitive and Somatic Processes in the Self-Regulation of Anxiety: Effects of Meditation versus Exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Combined pharmacological and behavioral treatment for agoraphobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

7 January 2021

Differential effectiveness of electromyograph feedback, verbal relaxation instructions, and medication placebo with tension headaches

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

7 January 2021

Relaxation-induced anxiety: paradoxical anxiety enhancement due to relaxation training.

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

7 January 2021

Assessing the impact of life changes: development of the Life Experiences Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2889%2980073-5

7 January 2021